Marisa Wexler, MS, senior science writer —

By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool to measure the severity of myasthenia gravis (MG) based on patient experiences. Called MG Symptoms PRO, this tool has the potential to aid clinical trials by better capturing a…

Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and Drug Administration (FDA) — to treat adults in the U.S. with generalized myasthenia gravis (gMG) who have the most common type of MG-driving antibody. Vyvgart currently is up for…

Throughout 2021, Myasthenia Gravis News has brought you coverage on the latest scientific advancements and clinical trials related to myasthenia gravis (MG). We look forward to continuing to be a resource to the MG community across 2022. Here are the top 10 most-read MG news stories of 2021, along with a…

Infants born to women with myasthenia gravis (MG) may develop a rare condition called transient neonatal myasthenia gravis (TNMG), which needs to be properly recognized in order to be appropriately managed, a new report highlights. “A neonate [newborn] born to a mother with MG is at risk for…

Treatment with Ultomiris (ravulizumab-cwvz), a complement-blocking therapy, quickly eased symptom severity in adults with generalized myasthenia gravis (gMG), according to data from a Phase 3 trial. Findings were shared at the Myasthenia Gravis Foundation of America (MGFA) Scientific Sessions 2021 in the presentation, “Efficacy and safety…

Vyvgart (efgartigimod) has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, the therapy’s developer, Argenx, announced. According to Argenx, this patient group represents about 85% of all with generalized MG. “Today is…

“Human-on-a-chip” technology developed by Hesperos can be used to model myasthenia gravis (MG), a new study shows. “This system has the potential to help researchers understand which mechanisms are driving a specific patient’s disease, including presence of particular autoantibodies [self-targeting antibodies], and could be used to further evaluate…

Zai Lab is planning — in the first half of 2022 — to ask Chinese authorities to approve efgartigimod (ARGX-113) as a treatment for generalized myasthenia gravis (gMG) in that country. The therapy, being developed by Argenx and designed to lessen the body’s immune attacks against…

The Institute for Clinical and Economic Review (ICER), an independent nonprofit that evaluates the prices and benefits of medications in the U.S., reported on the efficacy and cost-effectiveness of Soliris (eculizumab) and efgartigimod. Its report found reasonable evidence that adding either of these medications to conventional care…

More adults with generalized myasthenia gravis (gMG) who were treated with efgartigimod in a Phase 3 trial experienced minimal or no symptoms than did those given a placebo, an analysis of new study data reported. Other analyses from the ADAPT trial highlighted the potential benefits of efgartigimod for people who are…